SCHEMBL3350818

SCHEMBL3350818

Nc1ccnc2c1ccc1cccnc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 5/20 0.62
CCR8 P51685 5/20 0.62
CCR5 P51681 3/20 0.62
L3MBTL1 Q9Y468 3/20 0.62
HSP90AA1 P07900 4/20 0.61
LMNA P02545 3/20 0.61
KDM4E B2RXH2 2/20 0.61
MAPT P10636 2/20 0.61
MMP2 P08253 2/20 0.61
TSHR P16473 2/20 0.61
GMNN O75496 1/20 0.61
TP53 P04637 1/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2D6 P10635 1/20 0.61
MMP9 P14780 1/20 0.61
ALOX15 P16050 1/20 0.61
NFKB1 P19838 1/20 0.61
MMP8 P22894 1/20 0.61
THPO P40225 1/20 0.61
MTOR P42345 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1071707 0.83 NR4A2 (0.59) CCR1CCR8CCR5L3MBTL1HSP90AA1
Phenanthroline SCHEMBL7613395 0.81 CCR1 (0.57) CCR1CCR8CCR5L3MBTL1HSP90AA1
Phenanthroline SCHEMBL8357993 0.81 CCR1 (0.57) CCR1CCR8CCR5L3MBTL1HSP90AA1
SCHEMBL30913269 0.81 NR4A2 (0.55) CCR1CCR8CCR5L3MBTL1HSP90AA1
SCHEMBL8632444 0.80 CCR1 (0.55) CCR1CCR8CCR5L3MBTL1HSP90AA1
SCHEMBL16550178 0.79 LMNA (0.56) CCR1CCR8CCR5L3MBTL1HSP90AA1
Phenanthroline SCHEMBL1232224 0.79 CCR1 (0.89) CCR1CCR8CCR5L3MBTL1HSP90AA1
Phenanthroline SCHEMBL31549890 0.79 CCR1 (0.89) CCR1CCR8CCR5L3MBTL1HSP90AA1
Phenanthroline SCHEMBL8690798 0.79 CCR1 (0.89) CCR1CCR8CCR5L3MBTL1HSP90AA1
Phenanthroline SCHEMBL11542337 0.79 CCR1 (0.89) CCR1CCR8CCR5L3MBTL1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673100-B2 Systems and methods for integrated solar photodialysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-13 US disclosed
US-11673100-B2 Systems and methods for integrated solar photodialysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-13 US disclosed
EP-3246963-B1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO LTD (KR) 2023-05-31 EP disclosed
US-11318424-B2 Light-driven ion-pumping membrane systems THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-05-03 US disclosed
EP-3693372-A1 BENZOFURO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) Samsung Display Co., Ltd. (KR) 2020-08-12 EP disclosed
US-20190217255-A1 SYSTEMS AND METHODS FOR INTEGRATED SOLAR PHOTODIALYSIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-07-18 US disclosed
US-20180065095-A1 LIGHT-DRIVEN ION-PUMPING MEMBRANE SYSTEMS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-03-08 US disclosed
US-20180065095-A1 LIGHT-DRIVEN ION-PUMPING MEMBRANE SYSTEMS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-03-08 US disclosed
US-9573117-B2 Catalyst precursors, catalysts and methods of producing same INSTITUTE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2017-02-21 US disclosed
EP-2634178-B1 QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF CHINESE ACAD INST CHEMISTRY (CN) 2016-08-24 EP disclosed
US-20140099571-A1 CATALYSTS MADE USING THERMALLY DECOMPOSABLE POROUS SUPPORTS INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2014-04-10 US disclosed
EP-2673084-A1 CATALYSTS MADE USING THERMALLY DECOMPOSABLE POROUS SUPPORTS Institut National De La Recherche Scientifique (CA) 2013-12-18 EP disclosed
US-8580704-B2 Catalyst precursors, catalysts and methods of producing same INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2013-11-12 US disclosed
EP-2634178-A1 QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF Institute Of Chemistry, Chinese Academy Of Sciences (CN) 2013-09-04 EP disclosed
US-20130225811-A1 QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) 2013-08-29 US disclosed
US-20130225811-A1 QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) 2013-08-29 US disclosed
US-20130071742-A1 LITHIUM ION BATTERIES GM Global Technology Operations LLC (US) 2013-03-21 US disclosed
WO-2012107838-A1 CATALYSTS MADE USING THERMALLY DECOMPOSABLE POROUS SUPPORTS INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2012-08-16 WO disclosed
US-20110294658-A1 CATALYST PRECURSORS, CATALYSTS AND METHODS OF PRODUCING SAME INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2011-12-01 US disclosed
WO-2010051619-A1 CATALYST PRECURSORS, CATALYSTS AND METHODS OF PRODUCING SAME INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225811-A1 QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF MAP3K21, MAP3K15, MAP3K14 CCR1 2770/4885CCR8 3215/4885CCR5 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.